Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
Study (n=31,290 propensity matched pairs) reports the 1-yr risk of net adverse clinical events was not significantly different between ticagrelor and clopidogrel (15.1% [3484/23 116 person-years] vs 14.6% [3290/22 587 person-years]; hazard ratio, 1.05 [95% CI, 1.00-1.10]; p=.06)
Source:
Journal of the American Medical Association
SPS commentary:
Authors’ of a related editorial highlight that current guidelines recommend ticagrelor as the preferred P2Y12 platelet inhibitor for patients with acute coronary syndrome, primarily based on a single large randomised clinical trial; and whilst the possibility of unmeasured confounders cannot be excluded from the current study, the benefits and risks associated with ticagrelor versus clopidogrel in routine practice merits attention.